Important information regarding COVID-19

Research Studies


We are currently recruiting patients for the research studies detailed below. If you have questions about or are interested in joining a specific study, please get in touch with us using the following contact information.

(480) 526-5441
(480) 526-5443 (Fax)
research@movementdisorders.us
Parkinson's In-Progress

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease

Parkinson's In-Progress

A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety, and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER.

We have an ongoing drug study that will furnish the study drug for free, and will offer free doctor visits during the entire duration of the study.

In-Progress

RESTORE: A clinical study of patients with symptomatic neurogenic orthostatic hypotension to assess sustained effects of droxidopa therapy.

We have an ongoing drug study that will furnish the study drug for free, and will offer free doctor visits during the entire duration of the study.

Parkinson's In-Progress

A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson’s Disease Patients.

Parkinson's On Hold due to COVID

A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson’s Disease.